SAN
DIEGO, Sept. 3, 2024 /PRNewswire/ -- Heron
Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology
company focused on improving the lives of patients by developing
best-in-class treatments to address some of the most important
unmet patient needs, announced today the appointment of Brett
Fleshman as Chief Business Officer. Mr.
Fleshman will contribute his 25 years of experience in
corporate and business development, commercial strategy, and
marketing of pharmaceuticals, biologics, and surgical devices to
the management team enabling the next phase of growth.
"Now is the right time to add substantial BD and M&A
experience to the management team at Heron, and I welcome Brett to
repeat the success we have enjoyed together in the past,"
said Craig Collard, Chief Executive Officer of Heron. "Brett
will be focused on driving substantial inorganic revenue growth to
leverage our established commercial team in the hospital and
community settings. He will also lead our investor relations
function with the goal of expanding our reach to strategic
biopharma and generalist investors."
Most recently, Brett Fleshman
served as Managing Director at NovaQuest Capital Management, a
leader in product-based financing for late-stage clinical and
commercial biopharmaceutical programs. While at NovaQuest, Brett
was responsible for deal sourcing, structuring nondilutive
investments, negotiations, diligence, and post-close investment
management. Prior to NovaQuest, Mr. Fleshman served as Vice
President of Strategy and Corporate Development for Veloxis
Pharmaceuticals, where he helped formulate a turnaround
commercialization strategy which led to the company's acquisition
in 2020 by Asahi Kasei. Previously, Mr. Fleshman held senior
commercial and business development roles at Cornerstone
Therapeutics, supporting numerous company acquisitions, asset
purchases and territory licenses to build thriving hospital and
rare disease businesses that helped lead to the company's
acquisition by Chiesi Pharmaceutici S.p.A. Throughout his career,
Mr. Fleshman has focused on developing efficient strategies for
commercializing new products and revitalizing distressed assets.
Earlier in his career, Mr. Fleshman also held senior marketing
roles at Ther-Rx Corporation and Genzyme Biosurgery, now Sanofi
Genzyme. Mr. Fleshman earned a degree in Business Administration
from the John M. Olin School of Business at Washington University.
"In the field of M&A we strive for opportunities to deliver
on a mandate for bringing products to such a comprehensive yet
specialized commercial team," said Mr. Fleshman. "Working with
Craig and many members of this team extensively in the past, we had
a reputation for a healthy cadence of deals and delivering strong
commercial results. It's great to be back and to offer Heron the
experience and contacts gained while financing late-stage and
commercial pharmaceutical companies."
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc. is a commercial-stage
biotechnology company focused on improving the lives of patients by
developing and commercializing therapeutic innovations that improve
medical care. Our advanced science, patented technologies, and
innovative approach to drug discovery and development have allowed
us to create and commercialize a portfolio of products that aim to
advance the standard-of-care for acute care and oncology patients.
For more information, visit www.herontx.com.
Forward-looking Statements
This news release contains "forward-looking statements" as
defined by the Private Securities Litigation Reform Act of 1995.
Heron cautions readers that forward-looking statements are based on
management's expectations and assumptions as of the date of this
news release and are subject to certain risks and uncertainties
that could cause actual results to differ materially. These risks
and uncertainties include, but are not limited to, risks and
uncertainties identified in the company's filings with
the Securities and Exchange Commission. Forward-looking
statements reflect our analysis only on their stated date, and
Heron takes no obligation to update or revise these statements
except as may be required by law.
Investor Relations and Media Contact:
Brett Fleshman
Chief Business Officer
Heron Therapeutics, Inc.
bfleshman@herontx.com
858-251-4400
View original content to download
multimedia:https://www.prnewswire.com/news-releases/heron-therapeutics-announces-appointment-of-brett-fleshman-as-chief-business-officer-302236304.html
SOURCE Heron Therapeutics, Inc.
